4.26 USD
-0.05 (-1.16%)
4.33 USD
+0.07 (+1.64%)
Overall ACB gets a fundamental rating of 3 out of 10. We evaluated ACB against 191 industry peers in the Pharmaceuticals industry. ACB has a bad profitability rating. Also its financial health evaluation is rather negative. ACB is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
ACB had negative earnings in the past year.
In the past year ACB had a positive cash flow from operations.
In the past 5 years ACB reported 4 times negative net income.
ACB had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
ACB has a Return On Assets of -7.78%. This is in the better half of the industry: ACB outperforms 69.63% of its industry peers.
ACB's Return On Equity of -11.07% is fine compared to the rest of the industry. ACB outperforms 71.73% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -7.78% | ||
| ROE | -11.07% | ||
| ROIC | N/A |
ROA(3y)-55.32%
ROA(5y)-62.11%
ROE(3y)-90.28%
ROE(5y)-91.51%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ACB's Gross Margin of 1.69% is in line compared to the rest of the industry. ACB outperforms 49.74% of its industry peers.
In the last couple of years the Gross Margin of ACB has declined.
ACB does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 1.69% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-29.39%
2. Health
2.1 Basic Checks
ACB does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ACB has more shares outstanding
The number of shares outstanding for ACB has been reduced compared to 5 years ago.
The debt/assets ratio for ACB has been reduced compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of -10.52, we must say that ACB is in the distress zone and has some risk of bankruptcy.
ACB's Altman-Z score of -10.52 is on the low side compared to the rest of the industry. ACB is outperformed by 72.77% of its industry peers.
ACB has a Debt/Equity ratio of 0.07. This is a healthy value indicating a solid balance between debt and equity.
ACB has a Debt to Equity ratio of 0.07. This is comparable to the rest of the industry: ACB outperforms 51.83% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.07 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -10.52 |
ROIC/WACCN/A
WACC8.59%
2.3 Liquidity
A Current Ratio of 3.41 indicates that ACB has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 3.41, ACB is in line with its industry, outperforming 54.97% of the companies in the same industry.
ACB has a Quick Ratio of 1.63. This is a normal value and indicates that ACB is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of ACB (1.63) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.41 | ||
| Quick Ratio | 1.63 |
3. Growth
3.1 Past
ACB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 57.85%, which is quite impressive.
The Revenue has grown by 23.87% in the past year. This is a very strong growth!
The Revenue has been growing slightly by 6.94% on average over the past years.
EPS 1Y (TTM)57.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-4.55%
Revenue 1Y (TTM)23.87%
Revenue growth 3Y11.86%
Revenue growth 5Y6.94%
Sales Q2Q%11.4%
3.2 Future
ACB is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 103.58% yearly.
ACB is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.91% yearly.
EPS Next Y-1574.6%
EPS Next 2Y178.87%
EPS Next 3Y73.82%
EPS Next 5Y103.58%
Revenue Next Year11.1%
Revenue Next 2Y9.83%
Revenue Next 3Y9.81%
Revenue Next 5Y7.91%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for ACB. In the last year negative earnings were reported.
Based on the Price/Forward Earnings ratio of 15.00, the valuation of ACB can be described as correct.
Compared to the rest of the industry, the Price/Forward Earnings ratio of ACB indicates a rather cheap valuation: ACB is cheaper than 81.15% of the companies listed in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 23.35. ACB is valued slightly cheaper when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 15 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
ACB's earnings are expected to grow with 73.82% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y178.87%
EPS Next 3Y73.82%
5. Dividend
5.1 Amount
ACB does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
4.26
-0.05 (-1.16%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners21.18%
Inst Owner Change54.99%
Ins Owners0.04%
Ins Owner ChangeN/A
Market Cap239.50M
Revenue(TTM)367.13M
Net Income(TTM)-58.89M
Analysts73.33
Price Target5.85 (37.32%)
Short Float %12.53%
Short Ratio4.01
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-402.09%
Min EPS beat(2)-587.94%
Max EPS beat(2)-216.23%
EPS beat(4)1
Avg EPS beat(4)815.79%
Min EPS beat(4)-587.94%
Max EPS beat(4)4494.06%
EPS beat(8)2
Avg EPS beat(8)364.08%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)0.81%
Min Revenue beat(2)-0.84%
Max Revenue beat(2)2.46%
Revenue beat(4)3
Avg Revenue beat(4)4.08%
Min Revenue beat(4)-0.84%
Max Revenue beat(4)13.79%
Revenue beat(8)6
Avg Revenue beat(8)4.16%
Revenue beat(12)8
Avg Revenue beat(12)3.93%
Revenue beat(16)9
Avg Revenue beat(16)2.81%
PT rev (1m)1.47%
PT rev (3m)-0.13%
EPS NQ rev (1m)0%
EPS NQ rev (3m)15.91%
EPS NY rev (1m)-682.17%
EPS NY rev (3m)-682.17%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.27%
Revenue NY rev (1m)2.19%
Revenue NY rev (3m)2.19%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 15 | ||
| P/S | 0.89 | ||
| P/FCF | N/A | ||
| P/OCF | 146.16 | ||
| P/B | 0.62 | ||
| P/tB | 0.7 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.26
EYN/A
EPS(NY)0.28
Fwd EY6.67%
FCF(TTM)-0.24
FCFYN/A
OCF(TTM)0.03
OCFY0.68%
SpS4.77
BVpS6.91
TBVpS6.12
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -7.78% | ||
| ROE | -11.07% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 1.69% | ||
| FCFM | N/A |
ROA(3y)-55.32%
ROA(5y)-62.11%
ROE(3y)-90.28%
ROE(5y)-91.51%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-29.39%
F-Score5
Asset Turnover0.49
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.07 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 86.37% | ||
| Cap/Sales | 5.6% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.41 | ||
| Quick Ratio | 1.63 | ||
| Altman-Z | -10.52 |
F-Score5
WACC8.59%
ROIC/WACCN/A
Cap/Depr(3y)56.47%
Cap/Depr(5y)106.5%
Cap/Sales(3y)8.76%
Cap/Sales(5y)35.04%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)57.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-4.55%
EPS Next Y-1574.6%
EPS Next 2Y178.87%
EPS Next 3Y73.82%
EPS Next 5Y103.58%
Revenue 1Y (TTM)23.87%
Revenue growth 3Y11.86%
Revenue growth 5Y6.94%
Sales Q2Q%11.4%
Revenue Next Year11.1%
Revenue Next 2Y9.83%
Revenue Next 3Y9.81%
Revenue Next 5Y7.91%
EBIT growth 1Y-6.76%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year122.51%
EBIT Next 3Y30.92%
EBIT Next 5Y26.54%
FCF growth 1Y87.09%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y101.77%
OCF growth 3YN/A
OCF growth 5YN/A
AURORA CANNABIS INC / ACB FAQ
Can you provide the ChartMill fundamental rating for AURORA CANNABIS INC?
ChartMill assigns a fundamental rating of 3 / 10 to ACB.
Can you provide the valuation status for AURORA CANNABIS INC?
ChartMill assigns a valuation rating of 2 / 10 to AURORA CANNABIS INC (ACB). This can be considered as Overvalued.
What is the profitability of ACB stock?
AURORA CANNABIS INC (ACB) has a profitability rating of 2 / 10.